XM does not provide services to residents of the United States of America.
S
S

Sanofi

News

IGM Biosciences Announces Refocusing of Sanofi Collaboration

BRIEF-IGM Biosciences Announces Refocusing of Sanofi Collaboration April 17 (Reuters) - IGM Biosciences Inc IGMS.O : IGM BIOSCIENCES ANNOUNCES REFOCUSING OF SANOFI COLLABORATION IGM BIOSCIENCES INC: AGREEMENT WITH SANOFI TO CREATE AND DEVELOP IGM AGONIST ANTIBODIES WILL NOW FOCUS EXCLUSIVELY ON IMMUNOLOGY/INFLAMMATION TARGETS IGM BIOSCIENCES INC: W
S

Sanofi: New frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis

BRIEF-Sanofi: New frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis April 17 (Reuters) - Sanofi SA SASY.PA : PRESS RELEASE: NEW 48-WEEK FREXALIMAB PHASE 2 DATA SUPPORT POTENTIAL FOR HIGH SUSTAINED EFFICACY IN MULTIPLE SCLEROSIS SANOFI HAS INITIATED GLOBAL PHASE 3 STUDIES OF FREXALIMAB IN RELAPSING MS AND NO
S

Sanofi Canada Invests $180M CAD To Build And Update Infrastructure To Minimize Environmental Footprint At Its Toronto Campus By 50%

BRIEF-Sanofi Canada Invests $180M CAD To Build And Update Infrastructure To Minimize Environmental Footprint At Its Toronto Campus By 50% April 16 (Reuters) - Sanofi SA SASY.PA : SANOFI CANADA INVESTS $180M CAD TO BUILD AND UPDATE INFRASTRUCTURE TO MINIMIZE ENVIRONMENTAL FOOTPRINT AT ITS TORONTO CAMPUS BY 50% Further company coverage: SASY.PA
S

IDT Australia jumps on master service agreement with Sanofi

BUZZ-IDT Australia jumps on master service agreement with Sanofi ** Shares of IDT Australia IDT.AX rise as much as 18% to A$0.105, set for best day since Nov. 27, 2023, if gains hold ** Pharmaceutical manufacturer says it entered into a Master Service Agreement with healthcare co Sanofi to advance mRNA-based vaccine formulation, among others ** Value of services to be provided by IDT under initial order of agreement estimated to be about A$3 million ($1.93 million) to A$3.5 million - co ** Stock
S

Eli Lilly's nationwide insulin pricing settlement called off

Eli Lilly's nationwide insulin pricing settlement called off By Brendan Pierson April 15 (Reuters) - A settlement between Eli Lilly LLY.N and purchasers of its insulin drugs that would have capped prices and provided $13.5 million to resolve claims that the company inflated the drugs' cost has fallen apart, after an unfavorable ruling from the judge overseeing the case.
S

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.